Ananda Pharma PLC - Confirmation of receipt of £168k R&D tax refund

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

10 November 2025

ANANDA PHARMA PLC 

("Ananda" or the "Company") 

Confirmation of receipt of £168k R&D tax refund

Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that it has received a Research and Development tax refund of AUD340,166.49 (£168,065.68 at the exchange rate on 07/11/2025) from the Australian Tax Office. The refund is in relation to the Phase 1 study completed in Australia between July 2024 and June 2025.

The Company expects to receive a further refund in Q3 2026, in relation to expenditure on the Phase 1 pharmacokinetic (PK) study completed in Australia between July 2025 and June 2026. This refund is expected to be approximately AUD500,000 based on current forecasts.

Ananda's Chief Executive Officer, Melissa Sturgess, commented: "Australia's strong regulatory environment as well as advantageous tax arrangements, where a 43.5% refundable tax rebate is available for eligible R&D expenditure, have served us well.  We can now deploy this refund into other clinical trial workstreams and look forward to continuing apace and updating shareholders as we progress."

The Phase I, Open-Label, Multiple Dose Study to Assess the Pharmacokinetics, Safety, Tolerability and Food Effect of MRX1 in Healthy Adults is sponsored by the Company's wholly owned Australian subsidiary, Tiamat Australia Pty Ltd, and run in partnership with Australian CRO Southern Star Research. The objectives of the study have been to assess the safety and tolerability of MRX1 and to assess the pharmacokinetic profile of MRX1 in both men and women.

The study commenced dosing on 15 July 2025 and last participant last visit was completed on 1 October 2025. A total of 19 participants were dosed (9 male and 10 female) across two dosing cohorts.

Ananda expects to receive final safety and tolerability data from the trial in Q4 2025, with the final study report including pharmacokinetic results to be finalised in Q1 2026. The data generated from this study will become part of the clinical data package supporting MRX1 in future regulatory filings with regulators such as the FDA, EMA and MHRA. It will also help to inform future clinical trial protocols and the development of suitable dosing regimens.

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh.

For more information, please visit our website:

To stay up to date with Ananda's news please follow our social media channels:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor

-Ends-

For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.  

https://investors.anandapharma.co.uk/link/e95vDe